SANTA FE, N.M.–(BUSINESS WIRE)– Specifica, een particulier bedrijf voor antilichaamtechnologie dat zich richt op innovatieve in vitro antilichaambibliotheken en ontdekkingstools, heeft vandaag een overeenkomst aangekondigd met het wereldwijde gezondheidsbedrijf Sanofi op grond waarvan Specifica’s gepatenteerde Generation 3 Antibody Discovery Platform zal worden overgebracht naar Sanofi. Het uitgebreide pakket voor technologieoverdracht zal de integratie van Specifica’s Gen 3-platform in Sanofi’s antilichaamdetectieprogramma’s mogelijk maken.

“We zijn absoluut verheugd om samen te werken met Sanofi en hun geavanceerde antilichaam-ontdekkingsteams door ons complete antilichaam-ontdekkingsplatform te bieden via een combinatie van Gen 3-bibliotheken, oplossingen voor antilichaamoptimalisatie en geïntegreerde ontdekkingstools”, aldus Ken Sharples, CEO en co- oprichter van Specifica. “We kijken uit naar de realisatie van onze samenwerking met Sanofi terwijl ze doorgaan met het ontwikkelen van levensveranderende behandelingen.”

Specifica Announces Antibody Discovery Platform Transfer Agreement with Sanofi

SANTA FE, N.M.–(BUSINESS WIRE)– Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, today announced an agreement with the global healthcare company Sanofi under which Specifica’s patented Generation 3 Antibody Discovery Platform will be transferred to Sanofi. The comprehensive technology transfer package will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs.

“We are absolutely delighted to partner with Sanofi and their cutting-edge antibody discovery teams by providing our complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools,” said Ken Sharples, CEO and co-founder of Specifica. “We look forward to the realization of our collaboration with Sanofi as they continue to pursue the development of life-changing treatments.”

Specifica’s Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences (CDRs) from natural human antibodies that have been purged of sequence-based developability liabilities. The Gen 3 discovery platform consistently yields a broad diversity of specific and developable antibodies with very high affinities, thereby avoiding downstream hit-to-lead optimization bottlenecks such as affinity maturation and developability optimization.

About Specifica

Specifica is a rapidly growing antibody engineering company specializing in the creation of exceptional antibody libraries, using next-generation sequencing for quality control at all steps of construction and validation. Specifica’s patented Generation 3 Antibody Library Discovery Platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering. Specifica provides its partners with exclusive libraries, each created from a unique donor diversity set not used for any other library, ensuring that each Gen 3 library is one of a kind. Specifica offers antibody library platforms in Fab, scFv and VHH formats. In addition to in-house antibody library designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs. The power of the Generation 3 Platform may be accessed by engaging Specifica to execute antibody discovery and optimization campaigns, or by full transfer of the platform technology. Additionally, Specifica recently introduced AbXtract^TM, a powerful suite of antibody informatics tools, through its software partner OpenEye. Specifica is headquartered in Santa Fe, New Mexico.

For more information, please visit www.specifica.bio and follow Specifica on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005134/en/

Contacts

Media Relations
Andrew Bradbury | +1 505 216 2434 abradbury@specifica.com